FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553203127> ?p ?o ?g. }

• W2553203127 endingPage "369" @default.
• W2553203127 startingPage "362" @default.
• W2553203127 abstract "In Alzheimer's disease, antipsychotic medications are often used for a period, with relief of symptoms, and then discontinued, after which relapse may occur. The authors sought to determine which neuropsychiatric symptoms predict relapse.In the Antipsychotic Discontinuation in Alzheimer's Disease trial, 180 patients with Alzheimer's disease and symptoms of agitation or psychosis were treated with risperidone for 16 weeks, after which patients who responded (N=110) were randomly assigned to continue risperidone for 32 weeks, to continue risperidone for 16 weeks followed by switch to placebo for 16 weeks, or to receive placebo for 32 weeks. As reported previously, discontinuation of risperidone was associated with a two- to fourfold increased risk of relapse over 16-32 weeks. In planned post hoc analyses, the authors examined associations between the 12 symptom domains in the Neuropsychiatric Inventory (NPI) and relapse in the first 16-week phase after randomization.Compared with patients with mild hallucinations or no hallucinations, patients with severe hallucinations as a presenting symptom at baseline had a higher likelihood of relapse (hazard ratio=2.96, 95% CI=1.52, 5.76). This effect was present for the subgroup with auditory hallucinations, but not the subgroup with visual hallucinations. Among patients with baseline hallucinations, 13 of 17 (76.5%) who discontinued risperidone relapsed, compared with 10 of 26 (38.5%) who continued risperidone (p<0.02). This group difference remained significant for severe (77.8%) compared with mild (36%) hallucinations. NPI domain scores after the initial open-treatment phase were not associated with relapse.Patients with severe baseline hallucinations were more likely to relapse after randomization, and the presence of baseline hallucinations was associated with a higher risk of relapse after discontinuation of risperidone compared with continued risperidone treatment. For patients with hallucinations, particularly auditory hallucinations, antipsychotic discontinuation should be approached cautiously because of high relapse risk." @default.
• W2553203127 created "2016-11-30" @default.
• W2553203127 creator A5000211187 @default.
• W2553203127 creator A5009314208 @default.
• W2553203127 creator A5017204389 @default.
• W2553203127 creator A5024035616 @default.
• W2553203127 creator A5030853392 @default.
• W2553203127 creator A5036718203 @default.
• W2553203127 creator A5042497043 @default.
• W2553203127 creator A5048166302 @default.
• W2553203127 creator A5052990124 @default.
• W2553203127 creator A5061934117 @default.
• W2553203127 creator A5065305795 @default.
• W2553203127 creator A5073618398 @default.
• W2553203127 creator A5089609002 @default.
• W2553203127 date "2017-04-01" @default.
• W2553203127 modified "2023-10-16" @default.
• W2553203127 title "Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer’s Disease: The Role of Hallucinations" @default.
• W2553203127 cites W168247529 @default.
• W2553203127 cites W1847168837 @default.
• W2553203127 cites W2008854521 @default.
• W2553203127 cites W2020705217 @default.
• W2553203127 cites W2046073886 @default.
• W2553203127 cites W2058161128 @default.
• W2553203127 cites W2058762304 @default.
• W2553203127 cites W2070822624 @default.
• W2553203127 cites W2071068165 @default.
• W2553203127 cites W2109916969 @default.
• W2553203127 cites W2111963393 @default.
• W2553203127 cites W2132871355 @default.
• W2553203127 cites W2144816857 @default.
• W2553203127 cites W2148080316 @default.
• W2553203127 cites W2151391567 @default.
• W2553203127 cites W2156220037 @default.
• W2553203127 cites W2167311298 @default.
• W2553203127 cites W2559732081 @default.
• W2553203127 doi "https://doi.org/10.1176/appi.ajp.2016.16020226" @default.
• W2553203127 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5378647" @default.
• W2553203127 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27855483" @default.
• W2553203127 hasPublicationYear "2017" @default.
• W2553203127 type Work @default.
• W2553203127 sameAs 2553203127 @default.
• W2553203127 citedByCount "20" @default.
• W2553203127 countsByYear W25532031272017 @default.
• W2553203127 countsByYear W25532031272018 @default.
• W2553203127 countsByYear W25532031272019 @default.
• W2553203127 countsByYear W25532031272020 @default.
• W2553203127 countsByYear W25532031272022 @default.
• W2553203127 crossrefType "journal-article" @default.
• W2553203127 hasAuthorship W2553203127A5000211187 @default.
• W2553203127 hasAuthorship W2553203127A5009314208 @default.
• W2553203127 hasAuthorship W2553203127A5017204389 @default.
• W2553203127 hasAuthorship W2553203127A5024035616 @default.
• W2553203127 hasAuthorship W2553203127A5030853392 @default.
• W2553203127 hasAuthorship W2553203127A5036718203 @default.
• W2553203127 hasAuthorship W2553203127A5042497043 @default.
• W2553203127 hasAuthorship W2553203127A5048166302 @default.
• W2553203127 hasAuthorship W2553203127A5052990124 @default.
• W2553203127 hasAuthorship W2553203127A5061934117 @default.
• W2553203127 hasAuthorship W2553203127A5065305795 @default.
• W2553203127 hasAuthorship W2553203127A5073618398 @default.
• W2553203127 hasAuthorship W2553203127A5089609002 @default.
• W2553203127 hasBestOaLocation W25532031271 @default.
• W2553203127 hasConcept C118552586 @default.
• W2553203127 hasConcept C126322002 @default.
• W2553203127 hasConcept C142724271 @default.
• W2553203127 hasConcept C15744967 @default.
• W2553203127 hasConcept C168563851 @default.
• W2553203127 hasConcept C204243189 @default.
• W2553203127 hasConcept C204787440 @default.
• W2553203127 hasConcept C207103383 @default.
• W2553203127 hasConcept C27081682 @default.
• W2553203127 hasConcept C2776412080 @default.
• W2553203127 hasConcept C2776921671 @default.
• W2553203127 hasConcept C2778715236 @default.
• W2553203127 hasConcept C2779727114 @default.
• W2553203127 hasConcept C2780057945 @default.
• W2553203127 hasConcept C2780494398 @default.
• W2553203127 hasConcept C44249647 @default.
• W2553203127 hasConcept C71924100 @default.
• W2553203127 hasConceptScore W2553203127C118552586 @default.
• W2553203127 hasConceptScore W2553203127C126322002 @default.
• W2553203127 hasConceptScore W2553203127C142724271 @default.
• W2553203127 hasConceptScore W2553203127C15744967 @default.
• W2553203127 hasConceptScore W2553203127C168563851 @default.
• W2553203127 hasConceptScore W2553203127C204243189 @default.
• W2553203127 hasConceptScore W2553203127C204787440 @default.
• W2553203127 hasConceptScore W2553203127C207103383 @default.
• W2553203127 hasConceptScore W2553203127C27081682 @default.
• W2553203127 hasConceptScore W2553203127C2776412080 @default.
• W2553203127 hasConceptScore W2553203127C2776921671 @default.
• W2553203127 hasConceptScore W2553203127C2778715236 @default.
• W2553203127 hasConceptScore W2553203127C2779727114 @default.
• W2553203127 hasConceptScore W2553203127C2780057945 @default.
• W2553203127 hasConceptScore W2553203127C2780494398 @default.
• W2553203127 hasConceptScore W2553203127C44249647 @default.
• W2553203127 hasConceptScore W2553203127C71924100 @default.
• W2553203127 hasIssue "4" @default.

• next